Boji Pharmaceutical: Intends to reduce its holdings through centralized bidding by no more than 2.667 million shares for repurchasing shares.

Boji Pharmaceuticals announced that the board of directors has agreed to reduce the shares repurchased for the purpose of maintaining the company's value and shareholder rights through centralized bidding. It is planned to reduce up to 2,667,000 shares, accounting for 0.69% of the company's total share capital. The reduction period is from March 19 to September 18, 2026, and the price will be determined by the secondary market. In 2024, the company has repurchased a total of 2,667,000 shares, with a total transaction amount of 15.0968 million yuan. The proceeds from the reduction will be used to supplement working capital, and this reduction will not lead to changes in control or total share capital. In addition, the controlling shareholder and its concerted action parties had collectively reduced 11,486,500 shares from September to December 2025.